vTv Therapeutics’ (VTVT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Friday, AnalystRatings.com reports. They currently have a $5.00 price objective on the biotechnology company’s stock.

“Our $5 PT was derived by using a weighted-average cost of capital of 24% for vTv to discount free cash flows from annual sales and royalty payments of azeliragon and TPP399 for each year and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then factoring in a 1% terminal growth rate and 26% clinical program probability of success.”,” the firm’s analyst wrote.

Other analysts have also issued reports about the company. Zacks Investment Research lowered vTv Therapeutics from a buy rating to a hold rating in a research report on Thursday, May 2nd. ValuEngine lowered vTv Therapeutics from a buy rating to a hold rating in a research report on Monday, June 3rd. Finally, Northland Securities reaffirmed a buy rating and issued a $8.00 target price on shares of vTv Therapeutics in a research report on Thursday, August 1st.

Shares of vTv Therapeutics stock opened at $1.29 on Friday. vTv Therapeutics has a one year low of $0.68 and a one year high of $6.09. The firm has a market capitalization of $69.83 million, a price-to-earnings ratio of -1.87 and a beta of -3.71. The business has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $1.70.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.63 million. On average, sell-side analysts predict that vTv Therapeutics will post -0.53 earnings per share for the current fiscal year.

In related news, major shareholder Ronald O. Perelman acquired 1,212,121 shares of the firm’s stock in a transaction on Tuesday, July 9th. The stock was purchased at an average cost of $1.65 per share, with a total value of $1,999,999.65. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Ronald O. Perelman acquired 150,000 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were bought at an average cost of $1.31 per share, with a total value of $196,500.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 3,786,363 shares of company stock valued at $6,196,499 over the last three months. Corporate insiders own 1.70% of the company’s stock.

An institutional investor recently bought a new position in vTv Therapeutics stock. Wedbush Securities Inc. acquired a new position in shares of vTv Therapeutics Inc (NASDAQ:VTVT) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 17,500 shares of the biotechnology company’s stock, valued at approximately $30,000. 3.71% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.

See Also: What are municipal bonds?

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.